The exact Deauville score, NABS score and high SUVmax predicts outcome in extranodal natural killer/T-cell lymphoma

Huang, Hian Liang; Ngam, Pei Ing; Tan, Kang Hai; Ng, David Chee Eng; Lim, Soon Thye; Chan, Jason Yongsheng

doi:10.1007/s12149-021-01598-4

Cited by 4 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Novel prognostic models have also been suggested in recent years for NKTCL, such as the NABS score featuring the inclusion of a high peripheral blood neutrophil-to-lymphocyte ratio (NLR) of >3.5 as a scoring criterion with validated independent significance for prediction of OS and progression-free survival (PFS) ( 34 ). High initial SUVmax of the most FDG-avid lesion on primary FDG-PET/CT scanning and post-treatment Deauville scores of 4-5 which precluded a PET complete metabolic response were both additionally assessed to be associated with worse OS and PFS; a further subgroup analysis in this study further reflected that the NABS score accurately predicted survival outcomes in cohorts irrespective of the attainment of a complete metabolic response as indicated by post-treatment Deauville scores of 1-3 ( 35 ). A consolidated view of the criteria used for each prognostic index can be found below for PTCL indices and specialized indices in Tables 1 , 2 respectively.…”

Section: Current Clinical Systems For Risk Stratificationmentioning

confidence: 86%

Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma

et al. 2023

Self Cite

View full text Add to dashboard Cite

Peripheral T-cell lymphoma (PTCL) and natural killer/T-cell lymphoma (NKTCL) are rare subtypes of non-Hodgkin’s lymphoma that are typically associated with poor treatment outcomes. Contemporary first-line treatment strategies generally involve the use of combination chemoimmunotherapy, radiation and/or stem cell transplant. Salvage options incorporate a number of novel agents including epigenetic therapies (e.g. HDAC inhibitors, DNMT inhibitors) as well as immune checkpoint inhibitors. However, validated biomarkers to select patients for individualized precision therapy are presently lacking, resulting in high treatment failure rates, unnecessary exposure to drug toxicities, and missed treatment opportunities. Recent advances in research on the tumor and microenvironmental factors of PTCL and NKTCL, including alterations in specific molecular features and immune signatures, have improved our understanding of these diseases, though several issues continue to impede progress in clinical translation. In this Review, we summarize the progress and development of the current predictive biomarker landscape, highlight potential knowledge gaps, and discuss the implications on novel therapeutics development in PTCL and NKTCL.

show abstract

Section: Current Clinical Systems For Risk Stratificationmentioning

confidence: 86%

Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…As the Deauville criteria differentiate five scores in metabolic activity, its application may not be limited to discrimination between PET-positive versus PET-negative results at the time of baseline imaging but may also have predictive value. Huang et al (2021) [45] have demonstrated a prognostic value of a Deauville score of 5 for true disease progression at end of treatment in extra-nodal natural killer/T-cell lymphoma. Therefore, discrimination of scores 4 and 5 as proposed by Barrington et al (2014) [46] may prove its value in differentiating patients at higher risk of vascular complications or relapse.…”

Section: Discussionmentioning

confidence: 99%

Performance of Deauville Criteria in [18F]FDG-PET/CT Diagnostics of Giant Cell Arteritis

et al. 2023

View full text Add to dashboard Cite

In this retrospective study, PET/CT data from 59 patients with suspected giant cell arteritis (GCA) were reviewed using the Deauville criteria to determine an optimal cut-off between PET positivity and negativity. Seventeen standardised vascular regions were analysed per patient by three investigators blinded to clinical information. Statistical analysis included ROC curves with areas under the curve (AUC), Cohen’s and Fleiss’ kappa (κ) to calculate sensitivity, specificity, accuracy, and agreement. According to final clinician’s diagnosis and the revised 2017 ACR criteria GCA was confirmed in 29 of 59 (49.2 %) patients. With a diagnostic cut-off ≥ 4 (highest tracer uptake of a vessel wall exceeds liver uptake) for PET positivity, all investigators achieved high accuracy (range, 89.8–93.2%) and AUC (range, 0.94–0.97). Sensitivity and specificity ranged from 89.7–96.6% and 83.3–96.7%, respectively. Agreement between the three investigators suggested ‘almost perfect agreement’ (Fleiss’ κ = 0.84) A Deauville score of ≥4 as threshold for PET positivity yielded excellent results with high accuracy and almost perfect inter-rater agreement, suggesting a standardized, reproducible, and reliable score in diagnosing GCA. However, the small sample size and reference standard could lead to biases. Therefore, verification in a multicentre study with a larger patient cohort and prospective setting is needed.

show abstract

“…On top of these clinical factors, a recent meta-analysis demonstrated that several indices derived from fluorodeoxyglucose-positron emission tomography/computerized tomography (FDG-PET/CT) imaging could predict survival outcomes in patients with extranodal NKTCL, suggesting that FDG-PET/CT is not only useful for the assessment of treatment response but also potentially valuable for the prognostication in clinical practice [ 28 ]. The inclusion of imaging-based indicators such as SUVmax values and Deauville scores into clinical prognostic models have been suggested to complement clinical prognostic models [ 29 ]. Interestingly, PET/CT imaging patterns may also predict tumor immune microenvironment subtype in NKTCL, with the immune-silenced PET/CT pattern conferring worse overall survival compared to others [ 30 ].…”

Section: Clinical Risk Stratification and Prognostication Models For Nk/t-cell Lymphomamentioning

confidence: 99%

Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma

Chan

Lim

Ong

2021

Life

Self Cite

View full text Add to dashboard Cite

Natural killer/T-cell lymphoma (NKTCL) is an Epstein–Barr virus-associated non-Hodgkin lymphoma linked to an aggressive clinical course and poor prognosis. Despite an improvement in survival outcomes with the incorporation of novel agents including immune checkpoint inhibitors in the treatment of NKTCL, a significant proportion of patients still relapse or remain refractory to treatment. Several clinical prognostic models have been developed for NKTCL patients treated in the modern era, though the optimal approach to risk stratification remains to be determined. Novel molecular biomarkers derived from multi-omic profiling have recently been developed, with the potential to improve diagnosis, prognostication and treatment of this disease. Notably, a number of potential biomarkers have emerged from a better understanding of the tumor immune microenvironment and inflammatory responses. This includes a recently described 3′UTR structural variant in the PD-L1 gene, which confers susceptibility to checkpoint immunotherapy. In this review, we summarize the biomarker landscape of NKTCL and highlight emerging biomarkers with the potential for clinical implementation.

show abstract

The exact Deauville score, NABS score and high SUVmax predicts outcome in extranodal natural killer/T-cell lymphoma

Cited by 4 publications

References 20 publications

Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma

Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma

Performance of Deauville Criteria in [18F]FDG-PET/CT Diagnostics of Giant Cell Arteritis

Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma

Contact Info

Product

Resources

About